Patients with acute leukemia who achieve a clinical and morphologic remission after induction chemotherapy almost always relapse sooner or later, unless they are treated further with some kind of consolidation or intensification therapy. Cassinat et al 1 demonstrated in a patient with acute promyelocytic leukemia (APL) that the change from a bone marrow replaced by leukemic cells to a bone marrow in complete morphologic remission was achieved by a mere 1-1.5 log reduction in the PML/RAR␣ copy number. In this patient, who experienced an early relapse, hybrid gene transcript levels during a short remission remained 3 logs above those measured in patients remaining in sustained clinical response. This implies that a morphologically normal bone marrow and normal blood counts are compatible with significant amounts of residual disease.
Minimal residual disease (MRD) or incomplete remission?
The term minimal residual disease (MRD) was created to describe disease that was detected only by laboratory techniques more sensitive than morphology, such as flow cytometry (immunologic MRD) or polymerase chain reaction (PCR) (molecular MRD). This residual disease was Correspondence: Dr E Paietta, Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA believed to be minimal, given that it was found in the absence of clinical signs or symptoms. That MRD may be a misnomer in many patients is now demonstrated with the use of quantitative PCR for novel fusion genes, thought to be pathognomonic of several hematologic malignancies. 2 Obviously, the ultimate goal of MRD assays is to guide therapeutic decisions by recognizing patients who responded well to therapy and thus should be spared further therapy and distinguishing them from patients in whom therapy must be continued or intensified to minimize the likelihood of clinical relapse. However, when interpreting residual disease one must distinguish between the postinduction situation when patients enter a morphologically defined, potentially incomplete remission and the time point at which patients have experienced maximal response to therapy and present with true MRD. Consequently, the implications of residual disease depend on when it was detected.
In the postinduction phase, flow cytometry, which optimally has the ability to detect as few as between one and five leukemic blasts among 10 4 normal cells, can be equally effective in the detection of residual leukemic cells in acute lymphocytic leukemia (ALL), as is qualitative allele-specific oligonucleotide PCR. 3 However, if we consider that the induction of a morphologic remission may result from not more than a reduction from 10 12 to 10 10 leukemic cells, 4 disease that is detectable at this sensitivity level is not minimal and should not qualify as MRD. Just as we have moved away from basing leukemia diagnosis merely on morphology, 5, 6 the emerging data on residual disease detectable after induction chemotherapy by laboratory techniques more sensitive than mere microscopic evaluation of bone marrow smears are compelling enough to let us redefine laboratory criteria for the characterization of remission. It is not surprising that early immunophenotypic evaluation of residual disease in acute myeloid leukemia (AML) and ALL patients in morphologic complete remission identifies prognostic risk groups. 4, [7] [8] [9] This supports the concept that current standards for evaluating response to induction chemotherapy only document that disease was sufficiently reduced to allow for normalization of bone marrow function. It is comforting that some consensus is emerging regarding the most predictive prognostic levels of postinduction disease as detected by flow cytometry which, in both ALL and AML, appear to lie between 0.01% and 0.035% leukemic cell involvement of a morphologically normal appearing bone marrow. 4, [7] [8] [9] We must keep in mind, however, that to reliably detect 0.01% of leukemic cells, flow cytometry is pushed to its extreme limits which may not be reached in every clinical routine laboratory due to variability in technical expertise.
With the introduction of quantitative PCR for the measurement of aberrant RNA transcript levels, it became apparent that the extent to which disease eradication with induction chemotherapy occurs varies among patients as does the amount of disease that is present at diagnosis. 1, [10] [11] [12] [13] Furthermore, distinct kinetics of reduction of molecular subclones resulting in the selective persistence or evolution of minor clones contribute to the diversity of postinduction disease. 13, 14 Observations with qualitative 15, 16 or quantitative 11 PCR indicating that molecular residual disease at the end of induction therapy is prognostically not informative must be viewed in the context of both this heterogeneity of postinduction patients with respect to the level of residual disease and the inherent variability of PCR determinations.
The proposal of Pui and Campana 17 to newly define remission in pediatric ALL based on immunologic and molecular MRD (ie leukemic involvement of Ͻ0.01% of nucleated bone marrow cells at the end of induction chemotherapy) has my whole-hearted support with two reservations: I object to the use of the term MRD for describing residual disease which remains detectable by flow cytometry. Novel terminology in addition to 'immunologic remission', possibly 'postinduction residual disease', may be more appropriate. Second, I believe that data which could be utilized for defining a 'molecular remission' have only recently begun to appear. Given the previously mentioned heterogeneity of postinduction patients with respect to their molecular levels of disease, it has become obvious that establishing a qualitative PCR status (positive vs negative), while of value in detecting an incomplete remission, is not sufficient for measuring true MRD. Quantitation of disease levels below 10 −5 is an absolute requirement to the clinical usefulness of PCR with respect to the prediction of long-term outcome in patients in sustained clinical remission. Unfortunately, sensitivity levels for PCR determinations vary, largely dependent upon the particular target gene sequence to be amplified, the primer combination chosen, and the quality of nucleic acid extractions. Additional technical aspects affect precise quantitation, most importantly the choice of reference genes used for normalization, as recently exemplified in a large transplant in CML study. 18 Undoubtedly, the clinical usefulness of molecular assessment of MRD is in its infancy. Just as attempts were made previously to standardize qualitative PCR, 19 multicenter efforts will be necessary to establish common protocols for quantitative PCR. Only after standardization is accomplished will it be feasible to come to a consensus on MRD levels which are compatible with long-term response for each disease type analyzed. Until then, method sections must be reviewed carefully before valid clinical correlations are drawn from the large number of papers reporting on MRD determination in leukemia. Some points of relevance for the rational interpretation of publications on MRD are discussed in more detail below, and summarized in Table 1 for immunologic monitoring and in Table 2 for molecular monitoring:
Immunologic monitoring (Table 1) It is important that residual disease is consistently studied in one tissue type, either bone marrow or peripheral blood, when patients are monitored serially. Evidence exists that levels of MRD are higher in bone marrow than peripheral blood, at least in AML 10, 12 and B-lineage ALL. 20 Recent data in pediatric T-lineage ALL seem to suggest the opposite, 20 possibly reflecting the distinct pathways of leukemic cell spread in various disease subtypes. If mononuclear cells were isolated prior to staining with antibodies, there is a good chance that leukemic cells have been inadvertently reduced or totally removed. Therefore, staining whole, unprocessed material is preferred. The quality of a tissue or cell preparation depends predominantly on the age of the sample, and the conditions of storage which can be an issue particularly for specimens shipped to reference laboratories for analysis. Intra-laboratory controls can ease those concerns. The use of multiparameter two-or threecolor flow cytometry is essential as it allows for the recognition of small numbers of leukemic cells among a large number of normal cells. To perform immunologic MRD monitoring it is helpful, if not essential, to know the antigen expression pattern (immunologic fingerprint) of the leukemic cells at disease presentation. Post induction or in remission, residual leukemic cells are detected based on these antigen characteristics. Two caveats pertain, one is the fact that recovering bone marrow cells may sometimes be misinterpreted as abnormal cells, because normal precursor cells share a significant number of antigens with leukemic blast cells in a given patient. The other caveat is that leukemic immunologic fingerprints can change with therapy. Both potential problems can be dealt with by testing comprehensive enough antibody panels and applying profound knowledge of normal hematopoietic antigen expression patterns to their interpretation. 
Molecular monitoring (Table 2)
The distinction between the analysis of RNA by reverse transcriptase PCR (RT-PCR) or of DNA by genomic PCR is important since the latter has the ability to detect targeted gene rearrangements, which are not actively expressed. In other words, a mutation may exist at the DNA level, but may never be transcribed into RNA. In particular in CML, there is an ongoing argument whether some hematopoietic cells from patients in long-term remission may persistently contain the BCR/ABL hybrid gene without it being transcribed. When the data of genomic DNA were compared with RT-PCR data for MRD detection in CML patients in long-term remission, it was found that transcriptionally silent BCR/ABL cells do occasionally exist, albeit at much lower frequency than sometimes suggested. 21, 22 A crucial potential pitfall in molecular follow-up studies lies in the variability of the integrity of the nucleic acid preparations. Brisco et al 23 suggested correcting PCR-based MRD measurements for variations in DNA amplifiability occurring after chemotherapy for ALL. Integrity of RNA or DNA preparations is best proven by co-amplification of a control sequence, preferentially one related to the target gene or gene transcript, eg the normal BCR gene in patients with BCR/ABL hybrid genes. The use of quantitative vs qualitative PCR determines the achievable level of sensitivity and above all the clinical usefulness of the data (as discussed). In the selection of primers, sequences shared by highly homologous, but not targeted genes must be avoided. For instance, if the gene or gene product to be measured, gene A, shares substantial sequence homology with gene B, a gene of no interest in a given study, choosing primers which result in amplification of both genes may give falsely positive results. Furthermore, the sensitivity level of PCR assays is markedly affected by primer choices. Interference with the sensitivity of PCR assays from comparable gene rearrangements in normal cells, to date, has been raised as a potential problem only in MRD studies for ALL patients where PCR studies target clonal rearrangements of immunoglobulin and T cell receptor genes, which also occur in normal cells. 24 Which reference gene to chose for normalization in the quantitation of PCR products is an ongoing challenge. 25 
Immunophenotyping vs molecular monitoring of residual disease
The most problematic aspect in the clinical relevance of a molecularly defined remission remains the small fraction of patients who can actually benefit from molecular evaluation, particularly in AML. Immunophenotypic evaluation of response by multiparameter flow cytometry requires that the leukemic cells express an antigen profile which differs from those observed on normal hematopietic precursor cells and are expected to be present in a remission bone marrow. Luckily, the detection of aberrant markers on leukemic cells is successful in the majority of patients with ALL or AML. 4, 7, [26] [27] [28] [29] [30] [31] Granted, chemotherapy may affect antigen expression patterns. 6 However, the high incidence of leukemia-associated immunophenotypes (80-85% of cases)
Bone Marrow Transplantation stands in sharp contrast to the percentage of patients with AML, who can be followed with cytogenetic markers or their molecular equivalents (eg AML1/ETO, PML/RAR␣, possibly FLT3 gene mutations). To date, AML subtypes with traceable molecular markers account for approximately 30% of patients in clinical trials. Another fraction demonstrate chromosome abnormalities which may be monitored by fluorescence in situ hybridization (FISH) (eg monosomies, deletions, hyperdiploidy), but present a problem when low-level disease, below the level of sensitivity accomplished by FISH, needs to be evaluated by PCR. Although approximately 100 times more sensitive than standard cytogenetics, the sensitivity level achieved by FISH (one cell in 10 3 ) is markedly below that desired for MRD detection (one cell in 10 5 ). The possibility that genetic defects detected by interphase FISH may not be actually translated and thus reflect 'silent' and physiologically potentially meaningless disease adds a significant complication to the interpretation of FISH data. The best currently known example for this concept stems from the differentiation inducing effect of all-trans retinoic acid (ATRA) therapy in APL which can lead to the finding of t (15;17) in mature granulocytes, destined to die and thus irrelevant in terms of residual disease detection. 32 Then there is the rather large portion of AML patients with apparently normal karyotype (30-40% of patients in most large clinical trials). In AML, the advantage offered by FISH is rather small, attributable, for instance, to the rare karyotypically normal patient with clinical and/or morphologic characteristics of APL which prompt the physician to order FISH, leading to the detection of a cryptic t (15;17) in the leukemic cells. 33 Of great clinical interest are patients who present with cryptic molecular markers, detected by PCR, which derive from chromosomal translocations with well-defined, prognostic significance, such as AML1/ETO (in patients lacking t [8;21] ), 34 CBF␤/MYH11 (in patients lacking inv [16] ) 35 or MLL-AF4 (in patients lacking t [4;11] ), 36 as data on their clinical implication in comparison to that of the standard cytogenetic translocations are scarce and controversial. 34, 37 Reports suggesting that FLT3 gene internal tandem duplications (ITDs) or other FTL3 gene mutations may be found in 25-30% of patients with AML and with high frequency in patients with a normal karyotype [38] [39] [40] may add a novel molecular tool to the repertoire of MRD detection. 41 Changes in the pattern of FLT3 mutations between diagnosis and relapse recently reported by Kottaridis et al 42 seem, however, to profoundly curtail this prospect.
Chances for molecular monitoring are considerably better in ALL. In pediatric ALL, approximately a quarter of patients express cytogenetically cryptic TEL/AML1 transcripts. In adult ALL, a similar percentage of patients contain BCR/ABL transcripts (resulting from the Philadelphia chromosome). Another sizable fraction of patients contain aberrations of the MLL gene which result from translocations or deletions involving chromosome 11 at q23. 2 Most importantly, in ALL there is the possibility to monitor monoclonality based on immunoglobulin or T cell receptor gene rearrangements, although this approach may harbor its own challenges.
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Which level of residual disease, if any, is compatible with cure?
The original reasoning behind the assessment of MRD was the assumption that cure could only be achieved if disease was eradicated at the molecular level. Possibly, this concept still applies in ALL, [45] [46] [47] [48] while observations with most sensitive PCR in myeloid leukemias leave no doubt that long-term remission or cure is compatible with what looks like persistent disease. [10] [11] [12] 49 Threshold amounts of MRD predictive of long-term remission vs relapse have been suggested. Interestingly, these values may differ with disease subtype. Rather than simply reflecting an expected and potentially prohibitive variability in technology and data interpretation, such differences may be biologically valid. Tobal et al found a 10-fold difference in MRD levels between patients in long-term remission from APL 12 and those with t(8;21) AML 10 using equivalent techniques. Levels up to 10 3 molecules of AML1/ETO and up to 2 × 10 2 molecules of PML/RAR␣ per g RNA from patients' bone marrows were found to be compatible with durable remission.
A summary of low-level disease detection

Postinduction residual disease
The first time low-level disease is routinely evaluated by immunophenotypic or molecular parameters is after induction chemotherapy. We agreed that disease detected at this stage is best addressed as postinduction residual disease. However, whether or not postinduction residual disease reflects a status of incomplete remission or already optimal response depends on the level to which disease has been reduced, as well as the level of disease compatible with remission in a given disease subtype. There is simply not enough information yet available to make this kind of distinction. The implications of postinduction residual disease remain a moving target also because they depend on the projected efficacy of treatment strategies. With the improvement of treatment modalities, expectations for disease reduction will be higher, such as after addition of ATRA to chemotherapy in APL, 37 or the introduction of the tyrosine kinase inhibitor STI571 in the management of CML. 50 Residual disease following therapy that is considered optimal by current standards implies a higher level of resistance of the malignant cells than if suboptimal therapies had been implied.
Molecular relapse
Whether the demonstration of low-level disease in hematologically normal bone marrows of patients with isolated extramedullary relapse [51] [52] [53] should be regarded as molecular relapse or disease left-over from an incomplete remission induction is semantic and may in part depend on the timeframe of events. Whatever the origin of disease, systemic therapy will be warranted in this situation. However, the question of what constitutes molecular relapse in a patient without any evidence of disease and whether it needs to be medically addressed remains a challenging one. In APL, evidence suggests that outcome may be improved if patients are treated at the time of solely molecular evidence of disease. 37 Is it, however, justified to speak about molecular relapse if extremely low levels of BCR/ABL are found in every single CML patient after allogeneic transplant 54, 55 and to suggest basing treatment decisions on molecular criteria, particularly in studies performed over long periods of times during which quantitative parameters for molecular monitoring were modified within the study group? 56 Consideration of molecular relapse may require the reappearance of disease following a period of molecular negativity, the reversal of a negative slope of test results or a rise in the level of disease above that determined to be compatible with remission in a particular disease, if applicable.
In vivo and in vitro purging in the control of MRD
A major concern with autologous stem cell transplantation (SCT) is the risk of reinfusing occult residual malignant cells with the harvest. That the PCR status of the stem cell collection does not necessarily correlate with outcome has been shown in certain subtypes of AML, 37, 57 while this conclusion is not supported by data in ALL. 58 Always remembering that relevant evidence is contributed by disease subtypes traceable by molecular markers, which in AML constitute half of the patient population, such discrepant information may be explained by a differential sensitivity of myelo-vs lymphoblasts to destruction in the freeze-thaw cycle prior to infusion, or by disparate benefits from a graftversus-leukemia response in AML vs ALL. As one would expect, high levels of residual disease in peripheral blood stem cell collections, defined as Ͼ1 × 10 3 immunophenotypically abnormal cells, correlated with the duration of relapse-free survival in a group of AML patients. 59 Benefits from in vivo purging during a preparative regimen for SCT or intensive maintenance chemotherapy and the significance of pre-in vivo purging minimal disease status for overall outcome appear to differ with disease subtype. 37, 47 This may merely reflect differences available in treatment options or have its basis in pathogenetic mechanisms. The literature offers a plethora of possibilities of how PCR results may predict for long-term outcome. At what time-point after transplant PCR negativity should be achieved, on how many occasions the PCR test must be negative to correlate with long-term remission, with what method of testing and what level of sensitivity, in my opinion, remains study-dependent. All existing data must be viewed in the context of most recent evidence with most sensitive quantitative PCR that PCR negativity may be an unnecessary and irrational goal.
Cure
At the other end of the spectrum of MRD nuances is the long-term remitter who, in the ideal case, presents without detectable disease or that level of disease which is compatible with disease-free survival. As our limits of disease detection keep changing and our PCR assays achieve an increasingly higher level of sensitivity, the number of patients testing negative for a molecular marker at some stage of their disease course seems to be diminishing. Thus, defining the lowest level of disease compatible with cure appears to have become the most rational goal for future MRD analyses.
The implications of MRD in a patient who otherwise fulfills all criteria for cure are elusive. If such low levels of disease reflect cells that carry only the primary genetic aberration but lack the necessary secondary transforming event, as suggested for AML1/ETO or CBF␤/MYH11 fusion transcripts in long-term remitters, 11,60,61 then we may actually be dealing with 'pseudo-MRD'. This possibility finds support in reports of leukemia-associated fusion transcripts in normal hematopoietic cells. 36, [62] [63] [64] If, on the other hand, other physiologic mechanisms are to be held responsible for this symbiosis, 65 and these cells have the genetic make-up to potentially cause relapse, then these few cells truly represent MRD with potential therapeutic consequences.
